- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Acute migrane attacks
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 520KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 90KB)
Rimegepant – March 2024
Rimegepant: Tablet (orally disintegrating) 75 mg; Nurtec® ODT
Last updated
30 May 2025